Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease

• Main Authors: Pia Runeberg-Roos, Elisa Piccinini, Anna-Maija Penttinen, Kert Mätlik, Hanna Heikkinen, Satu Kuure, Maxim M. Bespalov, Johan Peränen, Enrique Garea-Rodríguez, Eberhard Fuchs, Mikko Airavaara, Nisse Kalkkinen, Richard Penn, Mart Saarma
• Format: Article
• Language: English
• Published: Elsevier 2016-12-01
• Series: Neurobiology of Disease
• Subjects: NRTN; Neurturin; GDNF; GFRα1; GFRα2; RET
• Online Access: http://www.sciencedirect.com/science/article/pii/S096999611630167X

In Parkinson's disease midbrain dopaminergic neurons degenerate and die. Oral medications and deep brain stimulation can relieve the initial symptoms, but the disease continues to progress. Growth factors that might support the survival, enhance the activity, or even regenerate degenerating dopamine neurons have been tried with mixed results in patients. As growth factors do not pass the blood-brain barrier, they have to be delivered intracranially. Therefore their efficient diffusion in brain tissue is of crucial importance. To improve the diffusion of the growth factor neurturin (NRTN), we modified its capacity to attach to heparan sulfates in the extracellular matrix. We present four new, biologically fully active variants with reduced heparin binding. Two of these variants are more stable than WT NRTN in vitro and diffuse better in rat brains. We also show that one of the NRTN variants diffuses better than its close homolog GDNF in monkey brains. The variant with the highest stability and widest diffusion regenerates dopamine fibers and improves the conditions of rats in a 6-hydroxydopamine model of Parkinson's disease more potently than GDNF, which previously showed modest efficacy in clinical trials. The new NRTN variants may help solve the major problem of inadequate distribution of NRTN in human brain tissue.